Publication:
European Position Statement on Diagnosis, and Treatment of Meniere's Disease.

dc.contributor.authorMagnan, Jacques
dc.contributor.authorÖzgirgin, O Nuri
dc.contributor.authorTrabalzini, Franco
dc.contributor.authorLacour, Michel
dc.contributor.authorEscamez, Antonio Lopez
dc.contributor.authorMagnusson, Mans
dc.contributor.authorGüneri, Enis Alpin
dc.contributor.authorGuyot, Jean Philippe
dc.contributor.authorNuti, Daniele
dc.contributor.authorMandalà, Marco
dc.date.accessioned2023-01-25T10:22:37Z
dc.date.available2023-01-25T10:22:37Z
dc.date.issued2018
dc.description.abstractMeniere Disease keeps challenges in its diagnosis and treatment since was defined by Prosper Meniere at the beginning of 19th Century. Several classifications and definition were made until now and speculations still exist on its etiology. As the etiology remains speculative the treatment models remain in discussion also. The European Academy of Otology and Neurotology Vertigo Guidelines Study Group intended to work on the diagnosis and treatment of Meniere's disease and created the European Positional Statement Document also by resuming the consensus studies on it. The new techniques on diagnosis are emphasized as well as the treatment models for each stage of the disease are clarified by disregarding the dilemmas on its treatment. The conservative, noninvasive and invasive therapeutic models are highlighted.
dc.identifier.doi10.5152/iao.2018.140818
dc.identifier.issn1308-7649
dc.identifier.pmcPMC6354459
dc.identifier.pmid30256205
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354459/pdf
dc.identifier.unpaywallURLhttps://doi.org/10.5152/iao.2018.140818
dc.identifier.urihttp://hdl.handle.net/10668/13000
dc.issue.number2
dc.journal.titleThe journal of international advanced otology
dc.journal.titleabbreviationJ Int Adv Otol
dc.language.isoen
dc.organizationHospital Universitario Virgen de las Nieves
dc.organizationCentro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica-GENYO
dc.page.number317-321
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.meshAnti-Bacterial Agents
dc.subject.meshBetahistine
dc.subject.meshConsensus
dc.subject.meshConservative Treatment
dc.subject.meshDenervation
dc.subject.meshDiuretics
dc.subject.meshEndolymphatic Sac
dc.subject.meshEuropean Union
dc.subject.meshGentamicins
dc.subject.meshHearing Loss, Sensorineural
dc.subject.meshHistamine Agonists
dc.subject.meshHumans
dc.subject.meshInjection, Intratympanic
dc.subject.meshMeniere Disease
dc.subject.meshNeurotology
dc.subject.meshOtolaryngology
dc.subject.meshPractice Guidelines as Topic
dc.subject.meshSteroids
dc.subject.meshVestibular Evoked Myogenic Potentials
dc.subject.meshVestibular Nerve
dc.subject.meshVestibule, Labyrinth
dc.titleEuropean Position Statement on Diagnosis, and Treatment of Meniere's Disease.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number14
dspace.entity.typePublication

Files